Pancreatic Arteriovenous Malformation: A Rare Cause of Upper Gastrointestinal Bleeding

배준화,권중구,한지민 대한내과학회 2020 대한내과학회 추계학술대회 Vol.2020 No.1

Efficacy of 7-day Tailored Therapy for Helicobacter pylori Eradication based on Clarithromycin Resistance

배준화,조형호,권중구,김은영 대한소화기학회 2023 대한소화기학회지 Vol.82 No.1

Background/Aims: Increasing resistance to clarithromycin (CAM) of Helicobacter pylori (H. pylori) is one of the main causes of recent decrease in eradication rate of standard triple therapy. The aim of this study was to evaluate the usefulness of 7-day tailored therapy based on the existence of CAM resistance. Methods: From January 2017 to May 2022, a total of 481 consecutive patients with H. pylori infection were recruited in Daegu Catholic University Medical Center. Treatment regimen was selected based on the result of CAM resistance test. Patients with CAM resistance (R group) were treated with bismuth-based quadruple therapy for 7 days. Patients without CAM resistance (S group) were treated with standard triple therapy for 7 days. Results: The overall H. pylori eradication rate was 89.4% (379 of 424) by per-protocol (PP) analysis. Patients with CAM resistance mutation included 166 patients (34.5%). The eradication rates of each group were 88.8% (135 of 152) and 89.7% (244 of 272) by PP analysis, for R and S group respectively. By intention-to-treat (ITT) analysis, the eradication rates were 81.3% (135 of 166) and 77.5% (244 of 315) for R and S group. CAM resistance was identified with a dual-priming oligonucleotide-based multiplex PCR. Conclusions: In spite of this high CAM resistance (34.5%), the eradication rate of 7-day tailored therapy based on the existence of CAM resistance was 89.4%. The 7-day tailored therapy based on CAM resistance could be an acceptable treatment selection strategy for H. pylori eradication.

Venous Thromboembolism in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy: Incidence and Effect on Prognosis

정한택,배준화,김호각,한지민 대한소화기학회 2023 대한소화기학회지 Vol.81 No.3

Background/Aims: This study evaluated the incidence of venous thromboembolism (VTE) in patients with advanced pancreatic ductal adenocarcinoma (PDAC) at the authors’ institution and analyzed the risk factors associated with VTE and the overall survival (OS). Methods: One hundred and seventy patients with locally advanced or metastatic PDAC who received palliative chemotherapy at Daegu Catholic University Medical Center from January 2011 to December 2020 were included. Results: During a median follow-up period of 341 days, 24 patients (14.1%) developed VTE. Cumulative incidence values of VTE were 4.7% (95% confidence interval [CI], 2.39-9.22) at 90 days, 9.9% (95% CI, 6.14-15.59) at 180 days, and 16.9% (95% CI, 11.50-24.36) at 360 days. Multivariate analysis showed that a carbohydrate antigen 19-9 (CA 19-9) level over 1,000 U/mL (hazard ratio [HR], 2.666; 95% CI, 1.112-6.389; p=0.028) and a history of alcohol consumption (HR, 0.327; 95% CI, 0.109-0.981; p=0.046) were significant factors associated with VTE. Patients with VTE showed a shorter median survival (347 days vs. 556 days; p=0.041) than those without VTE. Multivariate analysis revealed VTE (HR, 1.850; 95% CI, 1.049-3.263; p=0.033) and CA 19-9 level over 1,000 U/mL (HR, 1.843; 95% CI, 1.113-3.052; p=0.017) to be significant risk factors associated with OS. Conclusions: The cumulative incidence of VTE in patients with advanced PDAC was 16.9% at 360 days. While a history of alcohol consumption was a protective factor, a high CA19-9 level was a risk factor for VTE. In addition, the occurrence of VTE was associated with poor prognosis.

A Case of Osseous Metaplasia in a Gastric Hyperplastic Polyp

김대현,배준화,권중구,김은영,조형호,조창호 대한내과학회 2022 대한내과학회 추계학술대회 Vol.2022 No.2

고식적 화학 요법 후 완전 관해된 췌장암 1예

이재진,정한택,배준화 대한췌장담도학회 2023 대한췌담도학회지 Vol.28 No.4

췌장암은 항암화학요법의 발전에도 불구하고 여전히 예후가 좋지 않으며, 5년 생존율은 13.9%에 불과하다. 저자들은 61세 여성 환자에서 고식적 항암화학요법 후 췌장암에 대한 완전관해가 이루어진 증례를 보고하는 바이다. 환자는 1개월 동안의 소화불량과 2 kg의 체중 감소 증상을 호소하여 내원하였고, 컴퓨터 단층촬영 검사에서 췌장 머리 부위에 18 mm 크기의 종괴가 확인되었다. 혈액검사 결과에서 간 기능 검사는 정상이었으나, CA 19-9 및 CEA 수치가 각각 3,965 U/mL와 38.2 ng/mL로 상승되어 있었다. 조직 획득을 위해 내시경초음파 유도 세침흡인조직검사를 시행하였고, 병리학적 검사 결과 췌장선암으로 확인되었다. 양전자 방출 단층촬영 및 췌장 자기공명영상을 포함한 추가적인 평가를 통해 간의 6번째 분절과 복막하부 림프절에 전이성 종괴가 확인되었다. 최종적으로, 환자는 4기 췌장암으로 진단되었다. 환자에게 보존적 화학요법으로 폴피리녹스 투여하였고, 치료 1년 후 잔여 종양은 사라졌다. 이후 수술 치료를 시행하였고, 현재 보조 항암화학요법을 시행중이다. 전이성 췌장암에서 항암화학요법으로 완전관해를 이룬 사례는 매우 드문 증례이기에 문헌고찰과 함께 보고하는 바이다. The prognosis for pancreatic cancer is still poor with a 5-year survival rate around 10%. We report a case of complete remission after palliative chemotherapy for pancreatic cancer in a 61-year-old-female. She presented with indigestion and weight loss. A computed tomography scan revealed a 1.8 cm mass in the pancreatic head. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) levels were elevated. The patient underwent endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) and the pathologic examination showed adenocarcinoma. Positron emission tomography (PET) and magnetic resonance imaging (MRI) of the pancreas showed a metastatic nodule in the S6 segment of the liver and a metastatic portocaval lymph node. The final diagnosis was stage IV pancreatic cancer. The patient received 24 cycles of palliative FOLFIRINOX regimen. Response evaluation demonstrated disappearance of all the lesions. She underwent pyloruspreserving pancreatoduodenectomy (PPPD). The pathologic examination of the surgical specimen showed complete remission of the pancreatic cancer. The patient is currently undergoing adjuvant chemotherapy.

Acute Cholangitis with Common Bile Duct Stone Caused by Lactococcus garvieae: A Case Report

이준석,한지민,정한택,배준화,김호각,권현희 대한췌장담도학회 2023 대한췌담도학회지 Vol.28 No.2

Lactococcus garvieae is a Gram-positive cocci that has been known to be a fish pathogen, and considered as a low virulence organism rarely associated with human infection. We report a case of acute cholangitis with common bile duct (CBD) stone and bacteremia by L. garvieae bacteremia in a 70-year-old male. The patient presented with epigastric pain and was diagnosed with two CBD stones. Blood culture obtained prior to empiric antimicrobial therapy with ceftizoxime sodium showed growth with Escherichia coli and L. garvieae. The bacteria were confirmed by matrix-assisted desorption/ionization time-of-flight mass spectrometry. Initial attempt at endoscopic biliary drainage failed, and the patient underwent percutaneous transhepatic biliary drainage and subsequent stone removal. He occasionally ingested raw fish and had a history of gastric ulcer with acid suppression therapy, which could be possible risk factors for L. garvieae infection. This is the first case of L. garvieae bacteremia in acute cholangitis.

만성변비의 비약물 치료

서명숙 ( Myeongsook Seo ),배준화 ( June Hwa Bae ) 대한소화기학회 2024 대한소화기학회지 Vol.83 No.5

Functional constipation is a common clinical diagnosis that affects approximately 14% of the world’s population. Non-pharmacological therapies often represent the initial steps in management and may include lifestyle adjustments or changes such as physical activity and diet. Pharmacological options have been used when the non-pharmacological approach has been ineffective. Biofeedback therapy, surgery, sacral nerve stimulation, botulinum toxin injection, and vibrating capsules can be considered in scenarios where the laxatives are ineffective. Biofeedback therapy is highly effective and safe in treating dyssynergic defecation, which affects more than half of patients with chronic constipation. This paper overviews non-pharmacological therapies for functional constipation. (Korean J Gastroenterol 2024;83:191-196)

Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients

박상형,김가희,김민준,김규원,박정빈,백지은,배준화,홍승욱,황성욱,양동훈,예병덕,변정식,명승재,양석균 연세대학교의과대학 2024 Yonsei medical journal Vol.65 No.5

Purpose: This study aimed to evaluate the safety of biologics and small molecules for the treatment of inflammatory bowel diseases (IBD) in patients receiving antirejection therapies after organ transplants. Materials and Methods: We reviewed the medical records of patients with IBD who received organ transplants at the Asan Medical Center between January 1989 and December 2021. We compared the parameters of patients receiving biologics or small molecules to those of patients without those therapies. Results: This study included a total of 53 patients (ulcerative colitis, 41; Crohn’s disease, 6; and gastrointestinal Behçet’s disease, 6). Among them, 15 patients were receiving biologics or small molecules and 38 were not. During a mean follow-up of 119 months, the proportion of patients experiencing severe infections was significantly higher in those treated with biologics or small molecules than in those not treated. However, other safety outcomes (e.g., malignancies, adverse events, including organizing pneumonia or hepatic failure, and death) were not different between the two groups. Kaplan–Meier curve analysis revealed no significant difference in the safety outcome rate related to the use of biologics or small molecules. During follow-up, eight patients underwent bowel resections for IBD. The rate of bowel resection was not different between the two groups. Conclusion: The use of biologics or small molecules for patients with IBD who received organ transplants did not show a significant difference in safety outcomes. However, the possibility of severe infections must be considered.